Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions

In 2018, Around USD 13 Billion was Invested in This Domain, Representing a 73% Increase in Capital Investments in This Domain, Compared to the Previous Year

Overview

Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions. In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma® (2019), RECELL® System (2018), AmnioFix® (2018), EpiFix® (2018), EpiBurn® (2018), Alofisel® (2018), LUXTURNA™ (2017), Yescarta® (2017), and Kymriah® (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies.

In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year. It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.

The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers.

This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed. The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future.

Scope of the Report

The ‘Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030’ report features an extensive study of the growing supply chain management software solutions market. The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies.

Amongst other elements, the report features:

A detailed assessment of the current market landscape, featuring a comprehensive list of over 160 technological platforms that are being used to manage the cell and advanced therapies supply chain, along with information on the different types of software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, TTS, and others), their key specifications and benefits (chain of identity and custody, compatibility and integration, data management and analytics, regulatory compliance, reliability and security, scalability, software-as-a-service, traceability, user-friendliness, workflow management, and others), affiliated modes of deployment (cloud and on-premises), scale of management (small enterprise, mid-size enterprise and large enterprise), end users (biobanks, cell therapy labs, hospitals, research institutes, commercial organizations, and others), applications (ordering and scheduling, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), regulatory certifications / accreditations (21 CFR Part 11, CLIA, FACT-JACIE, GAMP 5, GDPR, HIPAA, and others), and key support services offered (customization, installation / implementation, maintenance, training / technical support, upgradation, validation and testing, and others).
An insightful company competitiveness analysis, taking into consideration the supplier power (based on their employee base and years of experience in the industry) and portfolio-related parameters, such as number of software solutions offered, affiliated modes of deployment, scale of management, end users, applications, regulatory certifications / accreditations, support services offered, and key platform specifications and benefits.
Comprehensive profiles of industry players that are currently offering software solutions for supply chain management, featuring an overview of the company, its financial information (if available), and a detailed description of its software system(s). Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.
A detailed review of the cell and advanced therapies supply chain, offering insights on the processes associated with various stages, such as donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up, along with information on cost requirements and existing opportunities for improvement in the supply chain management practices.
A qualitative assessment of the current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators / payers) involved in the cell and advanced therapies supply chain, featuring a summary of the diverse needs and areas of concern, along with our opinion (based on past and prevalent trends) on how the industry is preparing to address such issues.
An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are engaged in this field.
An analysis of the partnerships that have been established in the domain, in the period between 2014 and Q3 2019, covering software licensing agreements, mergers and acquisitions, product development agreements, product integration agreements, distribution agreements, asset purchase agreements, and other relevant deals.
A detailed analysis of the platform utilization use cases where aforementioned software systems were leveraged by various stakeholders in the domain, in the period between 2014 and Q3 2019, highlighting the ways in which companies have implemented such systems to improve / optimize various supply chain-related processes of cell and advanced therapies.
An in-depth analysis of the cost saving potential across various processes of the cell and advanced therapies supply chain that can be brought about by the implementation of bespoke and integrated technological solutions / software systems.
A case study on COPs, featuring insights on their key functions and implementation strategies, while also considering their strategic position and connectivity with other adjacent systems within the cell and advanced therapies supply chain. In addition, it provides a brief discussion on the growing popularity of COPs on the social media platform, Twitter.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, and TTS), [B] applications (donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), [C] modes of deployment (cloud and on-premises), [D] end users (biobanks, cell therapy labs, hospitals, research institutes, and commercial organizations), and [E] key geographical regions (North America, Europe and Asia-Pacific).

In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Bryan Poltilove (Vice President and General Manager, Thermo Fisher Scientific)
Jacqueline Barry (Chief Clinical Officer, Cell and Gene Therapy Catapult)
Jill Maddux (Director, Cell and Gene Therapy Product Strategy, McKesson) and Divya Iyer (Senior Director, Corporate Strategy and Business Development, McKesson)
Martin Lamb (Chief Business Officer, TrakCel)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Context and Background
3.2. An Introduction to Cell and Advanced Therapies
3.2.1. Classification of Advanced Therapy Medicinal Products
3.2.2. Current Market Landscape
3.3. Cell and Advanced Therapies Supply Chain
3.3.1. Key Processes
3.3.1.1. Donor Eligibility Assessment
3.3.1.2. Sample Collection
3.3.1.3. Manufacturing
3.3.1.4. Logistics
3.3.1.5. Patient Verification and Treatment Follow-up
3.3.2. Challenges Associated with the Cell and Advanced Therapies Supply Chain
3.3.2.1. Process Standardization
3.3.2.2. Process Qualification
3.3.2.3. Chain of Custody Documentation
3.3.2.4. Capacity Scheduling and Resource Utilization
3.3.2.5. Packaging and Shipping Qualification
3.3.2.6. Validation of Storage Containers
3.4. Software Solutions for Cell and Advanced Therapies Supply Chain Management
3.4.1. Cell Orchestration Platform
3.4.2. Enterprise Manufacturing System
3.4.3. Inventory Management System
3.4.4. Laboratory Information Management System
3.4.5. Logistics Management System
3.4.6. Patient Management System
3.4.7. Quality Management System
3.4.8. Tracking and Tracing System
3.5. Growth Drivers and Roadblocks
3.6. Emergence of Digital Technologies in Supply Chain Management
3.6.1. Blockchain Technology
3.6.2. Internet of Things
3.6.3. Augmented Reality
3.6.4. Big Data Analytics
3.6.5. Artificial Intelligence

4. CURRENT MARKET LANDSCAPE

4.1. Chapter Overview
4.2. Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape
4.2.1. Analysis by Type of Software Solution
4.2.2. Analysis by Key Specification and Benefit
4.3.3. Analysis by Application
4.3.4. Analysis by End User
4.3.5. Analysis by Mode of Deployment
4.3.6. Analysis by Scale of Management
4.3.7. Analysis by Regulatory Certifications / Accreditations
4.3. Cell and Advanced Therapies Supply Chain Management: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Location of Headquarters
4.2.3. Analysis by Size of Company
4.3.4. Analysis by Support Services Offered
4.3.5. Leading Developers: Analysis by Number of Software Solutions

5. COMPANY COMPETITIVENESS ANALYSIS

5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. Competitiveness Analysis: Overview of Supply Chain Management Software Solution Providers
5.4.1. Small-sized Companies
5.4.2. Mid-sized Companies
5.4.3. Large Companies

6. CORE SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS: COMPANY PROFILES

6.1. Chapter Overview
6.2. Brooks Life Sciences
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. BiobankPro®: Software Description
6.2.4. Recent Developments and Future Outlook
6.3. Cryoport
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Cryoportal®: Software Description
6.3.4. Recent Developments and Future Outlook
6.4. MasterControl
6.4.1. Company Overview
6.4.2. MasterControl Platform™: Software Description
6.4.3. Recent Developments and Future Outlook
6.5. SAP
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. SAP S/4HANA®: Software Description
6.5.4. Recent Development and Future Outlook
6.6. Savsu Technologies
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. evo® Cold Chain 2.0™: Software Description
6.6.4. Recent Development and Future Outlook
6.7. TraceLink
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Digital Supply Chain Platform: Software Description
6.7.4. Recent Developments and Future Outlook

7. CELL ORCHESTRATION PLATFORMS: EMERGING TRENDS AND PROFILES OF KEY PLAYERS

7.1. Chapter Overview
7.2. Supply Chain Orchestration Platforms
7.2.1. Key Functions of Supply Chain Orchestration Platforms
7.2.2. Advantages of Supply Chain Orchestration Platforms
7.2.3. Supply Chain Orchestration Platform Implementation Strategies
7.2.3.1. Building the Required Foundation
7.2.3.2. Incorporating an Appropriate Scheduling System
7.2.3.3. Integration with Core Systems / Processes
7.3. Supply Chain Orchestration Platform: Trends on Twitter
7.3.1. Scope and Methodology
7.3.2. Historical Trends in Volume of Tweets
7.3.3. Popular Keywords
7.4. Key Industry Players
7.4.1. Be The Match BioTherapies®
7.4.1.1. Company Overview
7.4.1.2. Financial Information
7.4.1.3. MatchSource®: Software Description
7.4.1.4. Recent Developments and Future Outlook
7.4.2. Clarkston Consulting
7.4.2.1. Company Overview
7.4.2.2. Cell Therapy Orchestration Platform: Software Description
7.4.2.3. Recent Developments and Future Outlook
7.4.3. Haemonetics
7.4.3.1. Company Overview
7.4.3.2. Financial Information
7.4.3.3. EdgeCell®: Software Description
7.4.3.4. Recent Developments and Future Outlook
7.4.4. Hypertrust Patient Data Care
7.4.4.1. Company Overview
7.4.4.2. Hypertrust X-Chain: Software Description
7.4.4.3. Recent Developments and Future Outlook
7.4.5. Lykan Bioscience
7.4.5.1. Company Overview
7.4.5.2. Unnamed Platform: Software Description
7.4.5.3. Recent Developments and Future Outlook
7.4.6. MAK-SYSTEM
7.4.6.1. Company Overview
7.4.6.2. T.C.S.: Software Description
7.4.6.3. Recent Developments and Future Outlook
7.4.7. sedApta Group
7.4.7.1. Company Overview
7.4.7.2. O.S.A.: Software Description
7.4.7.3. Recent Developments and Future Outlook
7.4.8. Stafa Cellular Therapy
7.4.8.1. Company Overview
7.4.8.2. Stafa Cellular Therapy Lab: Software Description
7.4.8.3. Recent Developments and Future Outlook
7.4.9. Title 21 Health Solutions
7.4.9.1. Company Overview
7.4.9.2. Cell Therapy Software: Software Description
7.4.9.3. Recent Developments and Future Outlook
7.4.10. TrakCel
7.4.10.1. Company Overview
7.4.10.2. Financial Information
7.4.10.3. TrakCel™ Cell Orchestration Platform: Software Description
7.4.10.4. Recent Developments and Future Outlook
7.4.11. Vineti
7.4.11.1. Company Overview
7.4.11.2. Financial Information
7.4.11.3. Personalized Therapy Management Software: Software Description
7.4.11.4. Recent Developments and Future Outlook

8. FUNDING AND INVESTMENT ANALYSIS

8.1. Chapter Overview
8.2. Types of Funding
8.3. Cell and Advanced Therapies Supply Chain Management: Recent Funding Instances
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions
8.3.5. Most Active Players: Analysis by Amount Invested
8.3.6. Most Active Investors: Analysis by Participation
8.3.7. Geographical Analysis by Amount Invested
8.4. Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Partner’s Focus Area
9.3.4. Analysis by Type of Software Solution
9.3.5. Most Active Players: Analysis by Number of Partnerships
9.3.6. Analysis by Regions
9.3.6.1. Most Active Players: Regional Analysis by Number of Partnerships
9.3.6.2. Intercontinental and Intracontinental Agreements

10. PLATFORM UTILIZATION USE CASES

10.1. Chapter Overview
10.2. Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases
10.2.1. Analysis by Year of Utilization
10.2.2. Analysis by User’s Focus Area
10.2.3. Analysis by Type of Software Solution
10.2.4. Most Active Players: Analysis by Number of Utilization Instances
10.2.5. Most Active Players: Regional Analysis by Number of Utilization Instances

11. VALUE CHAIN ANALYSIS

11.1. Chapter Overview
11.2. Cell and Advanced Therapies Value Chain
11.2. Cell and Advanced Therapies Value Chain: Cost Distribution
11.3.1. Donor Eligibility Assessment
11.3.2. Sample Collection
11.3.3. Manufacturing
11.3.4. Logistics
11.3.5. Patient Verification and Treatment Follow-up

12. STAKEHOLDER NEEDS ANALYSIS

12.1. Chapter Overview
12.2. Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders
12.2.1. Comparison of Stakeholder Needs

13. COST SAVINGS ANALYSIS

13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030
13.3.1. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030
13.3.2. Cost Saving Potential in Sample Collection, 2019-2030
13.3.3. Cost Saving Potential in Manufacturing, 2019-2030
13.3.4. Cost Saving Potential in Logistics, 2019-2030
13.3.5. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030

14. MARKET FORECAST

14.1. Chapter Overview
14.2. Key Assumptions and Forecast Methodology
14.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030
14.3.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application
14.3.1.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030
14.3.1.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030
14.3.1.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030
14.3.1.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030
14.3.1.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030
14.3.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User
14.3.2.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030
14.3.2.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, 2019-2030
14.3.2.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, 2019-2030
14.3.2.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030
14.3.2.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, 2019-2030
14.3.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution
14.3.3.1. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.2. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.3. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.4. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.5. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.6. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.7. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment
14.3.4.1. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030
14.3.4.2. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030
14.3.5. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography
14.3.5.1. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030
14.3.5.2. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030
14.3.5.2. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030
14.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment
14.4.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030
14.4.1.1. Patient Management Systems Market for Donor Eligibility Assessment, 2019-2030
14.4.1.1.1. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030
14.4.1.1.2. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030
14.4.1.2. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, 2019-2030
14.4.1.2.1. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030
14.4.1.2.2. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030
14.4.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030
14.4.2.1. Inventory Management Systems Market for Sample Collection, 2019-2030
14.4.2.1.1. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.1.2. Inventory Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.2. Laboratory Information Management Systems Market for Sample Collection, 2019-2030
14.4.2.2.1. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.2.2. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.3. Logistics Management Systems Market for Sample Collection, 2019-2030
14.4.2.3.1. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.3.2. Logistics Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.4. Quality Management Systems Market for Sample Collection, 2019-2030
14.4.2.4.1. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.4.2. Quality Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.5. Supply Chain Orchestration Platforms Market for Sample Collection, 2019-2030
14.4.2.5.1. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.5.2. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030
14.4.3.1. Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030
14.4.3.1.1. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.1.2. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.2. Inventory Management Systems Market for Manufacturing, 2019-2030
14.4.3.2.1. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.2.2. Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.3. Laboratory Information Management Systems Market for Manufacturing, 2019-2030
14.4.3.3.1. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.3.2. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.4. Quality Management Systems Market for Manufacturing, 2019-2030
14.4.3.4.1. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.4.2. Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.5. Supply Chain Orchestration Platforms Market for Manufacturing, 2019-2030
14.4.3.5.1. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.5.2. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030
14.4.4.1. Logistics Management Systems Market for Logistics, 2019-2030
14.4.4.1.1. Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030
14.4.4.1.2. Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030
14.4.4.2. Supply Chain Orchestration Platforms Market for Logistics, 2019-2030
14.4.4.2.1. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030
14.4.4.2.2. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030
14.4.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030
14.4.5.1. Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030
14.4.5.1.1. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030
14.4.5.1.2. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030
14.4.5.2. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030
14.4.5.2.1. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030
14.4.5.2.2. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030

15. EXECUTIVE INSIGHTS

15.1. Chapter Overview
15.2. Thermo Fisher Scientific
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Bryan Poltilove, Vice President and General Manager
15.3. Cell and Gene Therapy Catapult
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer
15.4. McKesson
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Jill Maddux, Director, Cell and Gene Therapy Product Strategy, and Divya Iyer, Senior Director, Corporate Strategy and Business Development
15.5. TrakCel
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Martin Lamb, Chief Business Officer

16. CONCLUDING REMARKS

16.1. Chapter Overview
16.2. Key Takeaways

17. APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS18. APPENDIX 2: TABULATED DATA19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1. Classification of Advanced Therapy Medicinal Products
Figure 3.2. Market Access Landscape of Key Cell and Advanced Therapies across Different Geographies
Figure 3.3. Key Processes of Cell and Advanced Therapies Supply Chain
Figure 3.4. Responsibilities of Stakeholders Involved in Cell and Advanced Therapies Supply Chain
Figure 3.4. Key Steps Involved in the Manufacturing of Cell and Advanced Therapies
Figure 3.5. Keys Steps Involved in Logistics Operations of Autologous Therapies
Figure 3.6. Comparison of Logistics Processes for Autologous and Allogeneic Therapies
Figure 3.7. Key Challenges Related to Cell and Advanced Therapies Supply Chain
Figure 3.8. Key Considerations for Transportation of Cell and Advanced Therapies
Figure 3.9. Temperature Variations across Cryogenic Vessels / Dewars for Storage of Cell and Advanced Therapies
Figure 3.10. Recommendations for Process Qualification of Cell and Advanced Therapies
Figure 3.11. Overview of Supply Chain Orchestration Platforms
Figure 3.12. Functions of Key Software Solutions for Cell and Advanced Therapies Supply Chain Management
Figure 3.13. Growth Drivers and Roadblocks to Software Solutions in Cell and Advanced Therapies Supply Chain
Figure 4.1. Cell and Advanced Therapies Supply Chain Management: Distribution by Type of Software Solution
Figure 4.2. Cell and Advanced Therapies Supply Chain Management: Distribution by Key Specifications and Benefits
Figure 4.3. Cell and Advanced Therapies Supply Chain Management: Distribution by Application
Figure 4.4. Cell and Advanced Therapies Supply Chain Management: Distribution by End User
Figure 4.5. Cell and Advanced Therapies Supply Chain Management: Distribution by Mode of Deployment
Figure 4.6. Cell and Advanced Therapies Supply Chain Management: Distribution by Scale of Management
Figure 4.7. Cell and Advanced Therapies Supply Chain Management: Distribution by Regulatory Certification / Accreditation
Figure 4.8. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Year of Establishment
Figure 4.9. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Geographical Location
Figure 4.10. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Company Size
Figure 4.11. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Services Offered
Figure 4.12. Leading Developers: Distribution by Number of Software Solutions
Figure 5.1. Competitiveness Analysis of Small-sized Supply Chain Management Software Solutions Providers
Figure 5.2. Competitiveness Analysis of Mid-sized Supply Chain Management Software Solutions Providers
Figure 5.3. Competitiveness Analysis of Large-sized Supply Chain Management Software Solutions Providers
Figure 6.1. Brooks Life Sciences: Net Sales, FY 2014 – H1 2019 (USD Million)
Figure 6.2. Cryoport: Net Sales, FY 2014 – H1 2019 (USD Million)
Figure 6.3. SAP: Net Sales, FY 2014 – H1 2019 (USD Million)
Figure 7.1. Standardization of Tasks by Supply Chain Orchestration Platforms
Figure 7.2. Key Functions of Supply Chain Orchestration Platforms
Figure 7.3. Advantages of Supply Chain Orchestration Platforms
Figure 7.4. Trends on Social Media: Historical Activity on Twitter, 2015-2018
Figure 7.5. Trends on Social Media: Popular Keywords
Figure 7.6. Be The Match BioTherapies®: Net Sales, FY 2013 – FY 2018 (USD Billion)
Figure 8.1. Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Figure 8.2. Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Figure 8.3. Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 8.4. Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Figure 8.5. Funding and Investments: Distribution by Type of Funding
Figure 8.6. Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 8.7. Popular Software Solutions: Distribution by Number of Funding Instances
Figure 8.8. Popular Software Solutions: Distribution by Amount Invested (USD Million)
Figure 8.9. Funding Instances: Year-wise Trend of Amount Invested across Different Software Solutions, 2014-Q3 2019 (USD Million)
Figure 8.10. Most Active Players: Distribution by Number of Instances
Figure 8.11. Most Active Players: Distribution by Capital Amount Raised (USD Million)
Figure 8.12. Most Active Investors: Distribution by Number of Instances
Figure 8.13. Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Figure 8.14. Funding and Investment Summary
Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 9.4. Partnerships and Collaborations: Distribution by Partner’s Focus Area
Figure 9.5. Partnerships and Collaborations: Distribution by Type of Software Solution
Figure 9.6. Partnerships and Collaborations: Year-wise Trend by Type of Software Solution
Figure 9.7. Most Active Players: Distribution by Number of Partnerships
Figure 9.8. Most Active Players: Regional Distribution by Number of Partnerships
Figure 9.9. Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Figure 10.1. Platform Utilization Use Cases: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 10.2. Platform Utilization Use Cases: Distribution by User’s Focus Area
Figure 10.3. Platform Utilization Use Cases: Distribution by Type of Software Solution
Figure 10.4. Platform Utilization Use Cases: Year-wise Trend by Type of Software Solution
Figure 10.5. Most Active Players: Distribution by Number of Utilization Instances
Figure 10.6. Most Active Players: Regional Distribution by Number of Utilization Instances
Figure 11.1. Key Processes of Cell and Advanced Therapies Value Chain
Figure 11.2. Cell and Advanced Therapies Value Chain: Cost Distribution
Figure 11.3. Cell and Advanced Therapies Value Chain: Donor Eligibility Assessment
Figure 11.4. Cell and Advanced Therapies Value Chain: Sample Collection
Figure 11.5. Cell and Advanced Therapies Value Chain: Manufacturing
Figure 11.6. Cell and Advanced Therapies Value Chain: Logistics
Figure 11.7. Cell and Advanced Therapies Value Chain: Patient Verification and Treatment Follow-up
Figure 12.1. Cell and Advanced Therapies Supply Chain Management: Stakeholders Needs Analysis
Figure 12.2. Comparison of Stakeholder Needs
Figure 13.1. Overall Cost Saving Potential of Supply Chain Management: Likely Scenarios
Figure 13.2. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030 (USD Million)
Figure 13.3. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 13.4. Cost Saving Potential in Sample Collection, 2019-2030 (USD Million)
Figure 13.5. Cost Saving Potential in Manufacturing, 2019-2030 (USD Million)
Figure 13.6. Cost Saving Potential in Logistics, 2019-2030 (USD Million)
Figure 13.7. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030 (USD Million)
Figure 14.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, 2019-2030 (USD Million)
Figure 14.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 14.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.6. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030 (USD Million)
Figure 14.7. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.8. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, 2019-2030 (USD Million)
Figure 14.9. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030 (USD Million)
Figure 14.10. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, 2019-2030 (USD Million)
Figure 14.11. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, 2019-2030 (USD Million)
Figure 14.12. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030 (USD Million)
Figure 14.13. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, 2019-2030 (USD Million)
Figure 14.14. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, 2019-2030 (USD Million)
Figure 14.15. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.16. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.17. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.18. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.19. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.20. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.21. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.22. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, 2019-2030 (USD Million)
Figure 14.23. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.24. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030 (USD Million)
Figure 14.25. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, 2019-2030 (USD Million)
Figure 14.26. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030 (USD Million)
Figure 14.27. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030 (USD Million)
Figure 14.28. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030 (USD Million)
Figure 14.29. Patient Management Systems Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 14.30. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.31. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.32. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 14.33. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.34. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.35. Inventory Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.36. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.37. Inventory Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.38. Laboratory Information Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.39. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.40. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.41. Logistics Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.42. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.43. Logistics Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.44. Quality Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.45. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.46. Quality Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.47. Supply Chain Orchestration Platforms Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.48. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, 2019-2030
Figure 14.49. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, 2019-2030
Figure 14.50. Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.51. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.52. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.53. Inventory Management Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.54. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.55. Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.56. Laboratory Information Management Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.57. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.58. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.59. Quality Management Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.60. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.61. Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.62. Supply Chain Orchestration Platforms Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.63. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, 2019-2030
Figure 14.64. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, 2019-2030
Figure 14.65. Logistics Management Systems Market for Logistics, 2019-2030 (USD Million)
Figure 14.66. Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.67. Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.68. Supply Chain Orchestration Platforms Market for Logistics, 2019-2030 (USD Million)
Figure 14.69. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030
Figure 14.70. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030
Figure 14.71. Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.72. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.73. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.74. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.75. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.76. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 (USD Million)

List of Tables

Table 3.1. Applications of Cell and Advanced Therapies
Table 3.2. Differences between Cell and Advanced Therapies and Biotechnology Products
Table 3.3. Cell and Advanced Therapies: Commercialized Products
Table 4.1. Cell and Advanced Therapies Supply Chain Management: Information on Type of Software Solution
Table 4.2. Cell and Advanced Therapies Supply Chain Management: Information on Key Software Specifications and Benefits
Table 4.3. Cell and Advanced Therapies Supply Chain Management: Information on Key Applications and End Users
Table 4.4. Cell and Advanced Therapies Supply Chain Management: Information on Mode of Deployment, Scale of Management and Key Regulatory Certifications / Accreditations
Table 4.5. Cell and Advanced Therapies Supply Chain Management: Developer Overview
Table 4.6. Cell and Advanced Therapies Supply Chain Management: Information on key Support Services Offered
Table 6.1. Brooks Life Sciences: Key Highlights
Table 6.2. Brooks Life Sciences: Key Characteristics of BiobankPro®
Table 6.3. Brooks Life Sciences: Recent Developments and Future Outlook
Table 6.4. Cryoport: Key Highlights
Table 6.5. Cryoport: Key Characteristics of Cryoportal®
Table 6.6. Cryoport: Recent Developments and Future Outlook
Table 6.7. MasterControl: Key Highlights
Table 6.8. MasterControl: Key Characteristics of MasterControl Platform™
Table 6.9. MasterControl: Recent Developments and Future Outlook
Table 6.10. SAP: Key Highlights
Table 6.11. SAP: Key Characteristics of SAP S/4HANA®
Table 6.12. SAP: Recent Developments and Future Outlook
Table 6.13. Savsu Technologies: Key Highlights
Table 6.14. Savsu Technologies: Funding Instances
Table 6.15. Savsu Technologies: Key Characteristics of evo® Cold Chain 2.0™
Table 6.16. Savsu Technologies: Recent Developments and Future Outlook
Table 6.17. TraceLink: Key Highlights
Table 6.18. TraceLink: Funding Instances
Table 6.19. TraceLink: Key Characteristics of Digital Supply Chain Platform
Table 6.20. TraceLink: Recent Developments and Future Outlook
Table 7.1. Be The Match BioTherapies®: Key Highlights
Table 7.2. Be The Match BioTherapies®: Key Characteristics of MatchSource®
Table 7.3. Be The Match BioTherapies®: Recent Developments and Future Outlook
Table 7.4. Clarkston Consulting: Key Highlights
Table 7.5. Clarkston Consulting: Key Characteristics of Cell Therapy Orchestration Platform
Table 7.6. Clarkston Consulting: Recent Developments and Future Outlook
Table 7.7. Haemonetics: Key Highlights
Table 7.8. Haemonetics: Key Characteristics of EdgeCell®
Table 7.9. Haemonetics: Recent Developments and Future Outlook
Table 7.10. Hypertrust Patient Data Care: Key Highlights
Table 7.11. Hypertrust Patient Data Care: Key Characteristics of Hypertrust X-Chain
Table 7.12. Hypertrust Patient Data Care: Recent Developments and Future Outlook
Table 7.13. Lykan Bioscience: Key Highlights
Table 7.14. Lykan Bioscience: Key Characteristics of Unnamed Cell Orchestration Platform
Table 7.15. Lykan Bioscience: Recent Developments and Future Outlook
Table 7.16. MAK-SYSTEM: Key Highlights
Table 7.17. MAK-SYSTEM: Key Characteristics of T.C.S.
Table 7.18. MAK-SYSTEM: Recent Developments and Future Outlook
Table 7.19. sedApta Group: Key Highlights
Table 7.20. sedApta Group: Key Characteristics of O.S.A.
Table 7.21. sedApta Group: Recent Developments and Future Outlook
Table 7.22. Stafa Cellular Therapy: Key Highlights
Table 7.23. Stafa Cellular Therapy: Key Characteristics of Stafa Cellular Therapy Lab
Table 7.24. Stafa Cellular Therapy: Recent Developments and Future Outlook
Table 7.25. Title 21 Health Solutions: Key Highlights
Table 7.26. Title 21 Health Solutions: Key Characteristics of Cell Therapy Software
Table 7.27. Title 21 Health Solutions: Recent Developments and Future Outlook
Table 7.28. TrakCel: Key Highlights
Table 7.29. TrakCel: Funding Instances
Table 7.20. TrakCel: Key Characteristics of TrakCel™ Cell Orchestration Platform
Table 7.31. TrakCel: Recent Developments and Future Outlook
Table 7.32. Vineti: Key Highlights
Table 7.33. Vineti: Funding Instances
Table 7.34. Vineti: Key Characteristics of Personalized Therapy Management Software
Table 7.35. Vineti: Recent Developments and Future Outlook
Table 8.1. Cell and Advanced Therapies Supply Chain Management: List of Funding Instances, 2014-Q3 2019
Table 8.2. Cell and Advanced Therapies Supply Chain Management: Summary of Investments
Table 9.1. Cell and Advanced Therapies Supply Chain Management: List of Partnerships, 2014-Q3 2019
Table 9.2. Most Active Players: Regional Distribution by Number of Partnerships
Table 10.1. Cell and Advanced Therapies Supply Chain Management: List of Platform Utilization Use Cases, 2014-Q3 2019
Table 15.1. Thermo Fisher Scientific: Key Highlights
Table 15.2. Cell and Gene Therapy Catapult: Key Highlights
Table 15.3. McKesson: Key Highlights
Table 15.4. TrakCel: Key Highlights
Table 16.1. Cell and Advanced Therapies Supply Chain Management: Key Takeaways of the Report
Table 17.1. List of Additional Supply Chain Management Software Solutions
Table 19.1. Cell and Advanced Therapies Supply Chain Management: Distribution by Type of Software Solution
Table 19.2. Cell and Advanced Therapies Supply Chain Management: Distribution by Key Specifications and Benefits
Table 19.3. Cell and Advanced Therapies Supply Chain Management: Distribution by Application
Table 19.4. Cell and Advanced Therapies Supply Chain Management: Distribution by End User
Table 19.5. Cell and Advanced Therapies Supply Chain Management: Distribution by Mode of Deployment
Table 19.6. Cell and Advanced Therapies Supply Chain Management: Distribution by Scale of Management
Table 19.7. Cell and Advanced Therapies Supply Chain Management: Distribution by Regulatory Certification / Accreditation
Table 19.8. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Year of Establishment
Table 19.9. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Geographical Location
Table 19.10. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Company Size
Table 19.11. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Services Offered
Table 19.12. Leading Developers: Distribution by Number of Software Solutions
Table 19.13. Brooks Life Sciences: Net Sales, FY 2014 – H1 2019 (USD Million)
Table 19.14. Cryoport: Net Sales, FY 2014 – H1 2019 (USD Million)
Table 19.15. SAP: Net Sales, FY 2014 – H1 2019 (USD Million)
Table 19.16. Trends on Social Media: Historical Activity on Twitter, 2015-2018
Table 19.17. Be The Match BioTherapies®: Net Sales, FY 2013 – FY 2018 (USD Billion)
Table 19.18. Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Table 19.19. Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Table 19.20. Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Table 19.21. Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Table 19.22. Funding and Investments: Distribution by Type of Funding
Table 19.23. Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Table 19.24. Popular Software Solutions: Distribution by Number of Funding Instances
Table 19.25. Popular Software Solutions: Distribution by Amount Invested (USD Million)
Table 19.26. Funding Instances: Year-wise Trend of Amount Invested across Different Software Solutions, 2014-Q3 2019 (USD Million)
Table 19.27. Most Active Players: Distribution by Number of Instances
Table 19.28. Most Active Players: Distribution by Capital Amount Raised (USD Million)
Table 19.29. Most Active Investors: Distribution by Number of Instances
Table 19.30. Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Table 19.31. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Table 19.32. Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.33. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 19.34. Partnerships and Collaborations: Distribution by Partner’s Focus Area
Table 19.35. Partnerships and Collaborations: Distribution by Type of Software Solution
Table 19.36. Partnerships and Collaborations: Year-wise Trend by Type of Software Solution
Table 19.37. Most Active Players: Distribution by Number of Partnerships
Table 19.38. Most Active Players: Regional Distribution by Number of Partnerships
Table 19.39. Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Table 19.40. Platform Utilization Use Cases: Cumulative Year-wise Trend, 2014-Q3 2019
Table 19.41. Platform Utilization Use Cases: Distribution by User’s Focus Area
Table 19.42. Platform Utilization Use Cases: Distribution by Type of Software Solution
Table 19.43. Platform Utilization Use Cases: Year-wise Trend by Type of Software Solution
Table 19.44. Most Active Players: Distribution by Number of Utilization Instances
Table 19.45. Most Active Players: Regional Distribution by Number of Utilization Instances
Table 19.46. Cell and Advanced Therapies Value Chain: Cost Distribution
Table 19.47. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030 (USD Million)
Table 19.48. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030 (USD Million)
Table 19.49. Cost Saving Potential in Sample Collection, 2019-2030 (USD Million)
Table 19.50. Cost Saving Potential in Manufacturing, 2019-2030 (USD Million)
Table 19.51. Cost Saving Potential in Logistics, 2019-2030 (USD Million)
Table 19.52. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Table 19.53. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Conservative Scenario, 2019-2030 (USD Million)
Table 19.54. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Base Scenario, 2019-2030 (USD Million)
Table 19.55. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.56. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Conservative Scenario, 2019-2030 (USD Million)
Table 19.57. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Base Scenario, 2019-2030 (USD Million)
Table 19.58. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.59. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.60. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
Table 19.61. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.62. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.63. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.64. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.65. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.66. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.67. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.68. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
Table 19.69. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Base Scenario, 2019-2030 (USD Million)
Table 19.70. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.71. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
Table 19.72. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
Table 19.73. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.74. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Conservative Scenario, 2019-2030 (USD Million)
Table 19.75. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Base Scenario, 2019-2030 (USD Million)
Table 19.76. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.77. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Conservative Scenario, 2019-2030 (USD Million)
Table 19.78. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Base Scenario, 2019-2030 (USD Million)
Table 19.79. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.80. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Conservative Scenario, 2019-2030 (USD Million)
Table 19.81. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Base Scenario, 2019-2030 (USD Million)
Table 19.82. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.83. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Conservative Scenario, 2019-2030 (USD Million)
Table 19.84. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Base Scenario, 2019-2030 (USD Million)
Table 19.85. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.86. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Conservative Scenario, 2019-2030 (USD Million)
Table 19.87. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Base Scenario, 2019-2030 (USD Million)
Table 19.88. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.89. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Conservative Scenario, 2019-2030 (USD Million)
Table 19.90. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Base Scenario, 2019-2030 (USD Million)
Table 19.91. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.92. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Conservative Scenario, 2019-2030 (USD Million)
Table 19.93. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Base Scenario, 2019-2030 (USD Million)
Table 19.94. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.95. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.96. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.97. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.98. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.99. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.100. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.101. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.102. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.103. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.104. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.105. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.106. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.107. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.108. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.109. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.110. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.111. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.112. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.113. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.114. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.115. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.116. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.117. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Base Scenario, 2019-2030 (USD Million)
Table 19.118. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.119. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.120. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.121. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.122. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.123. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.124. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.125. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 19.126. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 19.127. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.128. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Conservative Scenario, 2019-2030 (USD Million)
Table 19.129. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Base Scenario, 2019-2030 (USD Million)
Table 19.130. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.131. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Conservative Scenario, 2019-2030 (USD Million)
Table 19.132. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Base Scenario, 2019-2030 (USD Million)
Table 19.133. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.134. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Conservative Scenario, 2019-2030 (USD Million)
Table 19.135. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Base Scenario, 2019-2030 (USD Million)
Table 19.136. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.137. Patient Management Systems Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.138. Patient Management Systems Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
Table 19.139. Patient Management Systems Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.140. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.141. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.142. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.143. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.144. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.145. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.146. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.147. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
Table 19.148. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.149. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.150. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.151. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.152. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.153. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.154. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.155. Inventory Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.156. Inventory Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.157. Inventory Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.158. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.159. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.160. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.161. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.162. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.163. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.164. Laboratory Information Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.165. Laboratory Information Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.166. Laboratory Information Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.167. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.168. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.170. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.171. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.172. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.173. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.174. Logistics Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.175. Logistics Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.176. Logistics Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.177. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.178. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.179. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.180. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.181. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.182. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.183. Quality Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.184. Quality Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.185. Quality Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.186. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.187. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.188. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.189. Quality Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.190. Quality Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.191. Quality Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.192. Supply Chain Orchestration Platforms Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.193. Supply Chain Orchestration Platforms Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.194. Supply Chain Orchestration Platforms Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.195. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.196. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.197. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.198. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.199. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.200. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.201. Enterprise Manufacturing Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.202. Enterprise Manufacturing Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.203. Enterprise Manufacturing Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19. 204. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19. 205. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19. 206. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19. 207. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19. 208. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19. 209. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.210. Inventory Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.211. Inventory Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.212. Inventory Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.213. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.214. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.215. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.216. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.217. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.218. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.219. Laboratory Information Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.220. Laboratory Information Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.221. Laboratory Information Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.222. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.223. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.224. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.225. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.226. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.227. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.228. Quality Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.229. Quality Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.230. Quality Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.231. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.232. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.233. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.234. Quality Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.235. Quality Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.236. Quality Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.237. Supply Chain Orchestration Platforms Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.238. Supply Chain Orchestration Platforms Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.239. Supply Chain Orchestration Platforms Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.240. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.241. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.242. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.243. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.244. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.245. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.246. Logistics Management Systems Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
Table 19.247. Logistics Management Systems Market for Logistics, Base Scenario, 2019-2030 (USD Million)
Table 19.248. Logistics Management Systems Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.249. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.250. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.251. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.252. Logistics Management Systems Market for Logistics: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.253. Logistics Management Systems Market for Logistics: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.254. Logistics Management Systems Market for Logistics: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.255. Supply Chain Orchestration Platforms Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
Table 19.256. Supply Chain Orchestration Platforms Market for Logistics, Base Scenario, 2019-2030 (USD Million)
Table 19.257. Supply Chain Orchestration Platforms Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.258. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.259. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.260. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.261. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.262. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.263. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.264. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
Table 19.265. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
Table 19.266. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.267. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.268. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.269. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.270. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.271. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.272. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.273. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
Table 19.274. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
Table 19.275. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.276. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.277. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.278. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.279. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.280. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.281. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

3P Biopharmaceuticals
4G Clinical
ABB
Abbott Informatics
Accenture
Adaptimmune Therapeutics
Adents
Adlib
Advanced Therapy Treatment Centres
Aegis
ÅF Industry
Agaram Technologies
AgiLab
AgileBio
Aithent
Alberta Cell Therapy Manufacturing
AllCells
AlloSource
Alvotech
Ambry Genetics
Amgen
Antares Vision
Anterogen
AntTail
AODocs
Aptean
AQ Manager
Aqxolt
ArisGlobal
ArunA Biomedical
AssurX
Asymptote
Atara Biotherapeutics
Atomos Hyla
Aurea
Autodesk
Autolus Therapeutics
Autoscribe Informatics
AveXis
Avita Medical
Baptist Memorial Health Care
BatchMaster Software
BayaTree
BC Platforms
Benchling
Benchmark
Bika Lab Systems
BioCision
BioFortis
Biokin Pharmaceutical
BioLife Solutions
BioSoft Integrators
Biovault
BIOVIA
Birlasoft
BizzMine
Blaze Systems
Blood Bank of Alaska
Bluechiip
bluecrux
Boyum IT Solutions
Bregal Sagemount
Bristol-Myers Squibb
Broekman Group
Brooks Life Sciences
Business Pointers
Caladrius Biosciences
Cambridge Biomedical
Cambridge University Hospitals NHS Foundation Trust
Camelot ITLab
Camstar Systems
Canaan Partners
Canadian Tissue Repository Network
CancerCare Manitoba
Capgemini
CareDx
CareMetx
Casdin Capital
Cell and Gene Therapy Catapult
Celularity
Celyad
Cenetron Diagnostics
Cerner
ChartFill
Chiesi Farmaceutici
Chiyoda System Technologies
CIMx
Clarkston Consulting
Cleveland Institute for Computational Biology
Clinical Ink
CloudLIMS
CobbleStone Software
Codon Software
Cognate BioServices
Comaiba
Conatus Pharmaceuticals
Concerto Cloud Services
Consummate Technologies
Continental Technology Solutions
COPAN Group
CORDET
Core Informatics
COSMO CONSULT
CoverMyMeds
Credit Suisse
CRISPR Therapeutics
Cryo Store
Cryogene Partners
CRYO-LEA
Cryoport
CryoStem
CryoTrack
CSAM
CSL Plasma
Cubixx Solutions
Cytolon
Dacos
Daedalus Software
Daiichi Sankyo
Data+ Research
DataArt
Database Integrations
Databyrån
Datacor
Dataworks Development
Deacom
Dell
Deloitte
Deltek
Dendreon
Deutsche Telekom
DFJ
DHL
Digi-Trax
DiscGenics
Docbyte
Docxellent
Dooile
Draper Associates
eHealth Technologies
EJADA
Elinext
Emad Trade House
Emerson
Endodiag
Enhanced Information Solutions
Enterprise System Partners
Epeius Biotechnologies
EuSoft
EVERSANA™
EXB Software
Excellis Health Solutions
EXTEDO
Extract Systems
e-Zest
Factorytalk
Factumsoft
Faubel
FedEx
Ferdinand Cabanne Biobank Center
FFF Enterprises
Fibrocell Science
Fidelity Biosciences
FirstMark Capital
Fishbowl
Fisher Clinical Services
Florida Hospital Cancer Center
Foch Hospital
F-Prime Capital Partners
Fred Hutchinson Cancer Research Center
French Epinal-Remiremont hospital group
Gamida Cell
GE Healthcare
GE Ventures
GEFCO
Gen9
Genea Biomedx
Genedata
Geneva Systems
Genohm
GenoLogics
Georgian Partners
Gilead Sciences
GlaxoSmithKline
Goldman Sachs
GPI Group
Gradalis
Green Cross LabCell
Grenoble Alpes University Hospital
Gulf Software Distribution
Gustave Roussy
Haemonetics
Haier Biomedical
HeapTrace Technology
Heat Biologics
HemaCare
Hemasoft Software
HighPoint Solutions
HighRes Biosolutions
Hitachi
Holostem Advanced Therapies
HP Enterprise Group
Human Stem Cells Institute
Hypertrust Patient Data Care
IBM
ICON
Ideagen
IDESS
IFS
Immetacyte
Immudex
ImmunoCellular Therapeutics
Indiana University Health
Infinity Group
Informeleon
Informeleon LifeScience Technologies
INFORS HT
Innovate UK
Innovation Connections
Institute of Medical Biology
Intelex
Interactive Biosoftware
Interactive Software
International Air Transport Association
International Genetically Engineered Machine Foundation
International Stem Cell
Iovance Biotherapeutics
IPERION
IQity
IQMS
IQVIA
iSpecimen®
I-Track Software
JAF Consulting
JAGGAER
Japan Tissue Engineering
JD Edwards
Jeena
Jeeves Information Systems
Jinfonet Software
KAIROS
Kayentis
KCAS Bioanalytical and Biomarker Services
KCSA Strategic Communications
Kiadis Pharma
Kite Pharma
KLATU Networks
KLP Enterprises
Kolon TissueGene
Körber Medipak Systems
Labcon
Labii
LabLogic Systems
LabLynx
LabVantage Solutions
LabWare
Larsen & Toubro Infotech
Lead Edge Capital
LifeConEx
LifeForce Capital
Limoges University Hospital
Liventa Bioscience
Llamawerx
Logistyx Technologies
Lonza
Lynden International
Magenta Therapeutics
MAK-SYSTEM
Management Science Associates
MARKEN
Marker Therapeutics
MasterControl
Mayo Clinic
Mazik Global
McKesson
MD Logistics
Medable
MedCision
Medical Research Network
Medical University of Graz
Medidata
Medipost
MediSapiens
Mediware Information Systems
MedNet Solutions
Mendix
Menlo Ventures
Mesoblast
Microsoft
MicroStrategy
Miller-Keystone Blood Center
Miltenyi Biotec
MiMedx Group
Mindteck
Modul-Bio
Moffitt Cancer Center
MolMed
Montefiore Medical Center
Montrium
Morphotek
Mount Sinai Medical
Mustang Bio
MyCellHub
National Blood Transfusion Centre
National Health Service Blood and Transplant
Neotrident
NetSuite
Network Scientific
New York Presbyterian Hospital
New York University Abu Dhabi
Nohla Therapeutics
Northern Alliance Advanced Therapies Treatment Centre
Noshaq
Nous Infosystems
Novartis
Novatek International
NTT Data
NuVasive
Nymi
Oak HC/FT
Oasis Infotech
Ocimum Biosolutions
Octal IT Solution
Octapharma
Octaware
Odoo
OmniComm
Oncobiomed
OpenSpecimen
OpenXcell
Opexa Therapeutics
OptiProERP
Oracle
Orthofix
OSIsoft
Osys
OTTR Complete Transplant Management
Oxford BioMedica
PAREXEL
Parsec
Pathomation
PCX International
Perseus PCI
Persistent Systems
Peter MacCallum Cancer Centre
Petrichor Healthcare Capital Management
Pharmicell
Pilgrim Quality Solutions
Planet Innovation
PleaseTech
Polar Speed
Polarion
POMS
Poseida Therapeutics
PricewaterhouseCoopers
prime4services
Priority Software
Priveq Investment Fund IV
Pro-curo Software
ProfitKey
Progeny Genetics
Progeny Software
ProMab Biotechnologies
ProteoGenex
Proteus Technologies
Q2 Solutions
QCMedchain
QIAGEN
Qualio
Quality by Design
Qualityze
Qualsys
Quick Life Science Group
Rand Group
RareChannels
Redefine
Reflow
Reliance Life Sciences
Replica Sistemi
Rfgen Software
ROC IT Solutions
Roche
Rockwell Automation
Rootstock Software
Roslin Cells
RURO
Sage
salamanderU
salesforce.com
Samsung BioLogics
Sanaria
Sanpower Group
SAP
SapioSciences
Sapphire
Sarah Cannon Blood Cancer Network
Sarla Technologies
Savsu Technologies
SciMed Technologies
Scottish National Blood Transfusion Service
Section 32
sedApta Group
SeerPharma
SemanticBits
Sensire
Sentry BioPharma Services
Shanghai Sunway Biotech
Shanghai Wellthinic Technology
ShipChain
Sibiono GeneTech
Siemens
Sintec
Software Point
SOLABS
SolutionsMax
Spark Therapeutics
Sparta
SPC Consultants
Specialised Therapeutics
SPI Pharma
STEINER
Stem Cell Technology Centre
Stemedica Cell Technologies
STEMSOFT Software
stemTrak
Strategic Information Group
SuprTecBox
Suzuken
Swinburne Universoty
Synergy Resources
SYSPRO
Systec & Services
SystImmune
SZIENZ
Tableau Software
Takeda Pharmaceutical
TECHNIDATA
Telegraph Hill Partners
Terumo
Terumo BCT
Tessa Therapeutics
Thaddeus
The CoFoundry
The Faktory
Thermo Fisher Scientific
Thrive Capital
TiGenix
Tissue Solutions
Titian Software
Title21 Health Solutions
Tmunity Therapeutics
Total Specific Solutions
Touchdown International
Toyo Business Engineering
TPG Capital
TraceLink
Triangle Research Labs
Triumvirate Environmental
TrueERP
UMass Memorial Health Care System
UNIGEN
United Cargo®
United Parcel Service
Unity™ Lab Services
University Cancer Institute
University Hospitals of Strasbourg and Strasbourg University
University of Bialystok
University of Illinois
University of Melbourne
University of Minnesota's Molecular and Cellular Therapeutics Unit
University of Sheffield
ValueLabs
Veeva Systems
Velos
Vericel
Verse
Versiti™
Vestrics Solutions
Vitro
Vitrolife
Vivaldi
VMware
Volition Capital
Vulcan Capital
WellSky™
Werum IT Solutions
WindMIL Therapeutics
Woodfield Distribution
WorkWise
World Courier
WuXi AppTec Advanced Therapies
XynManagement
Xyntek
Y Combinator
Yale-New Haven Hospital
Yokogawa Solution Service
ZenBio
Zenith Technologies

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4396EUR$4,499USD£3,670GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7815EUR$7,999USD£6,525GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15632EUR$15,999USD£13,050GBP

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

CAR T Cell Therapy Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication, Target Antigens, Key Geographical Regions, Key Players and Sales Forecast

Oncology Precision Medicine Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted, Route of Administration, Type of Molecule, Drug Class, Key Geographical Regions, Leading Drug Developers and Sales Forecast

T-Cell Therapy Market by Modality, Therapy Type, Indication - Global Forecast 2025-2030

Global Pharmacogenomics Market by Offering (Instrument, Consumables, Software), Technology (PCR, Sequencing, Microarray), Application (Oncology, Mental Health, Cardiology, Neurology, Infectious Disease), End User (Hospitals, Academic) - Forecast to 2031

CAR T-Cell Therapy for Multiple Myeloma - Market Insight, Epidemiology and Market Forecast - 2034